NASDAQ:VRCA

Verrica Pharmaceuticals Stock Forecast, Price & News

$12.69
-1.00 (-7.30 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$12.50
Now: $12.69
$13.93
50-Day Range
$13.24
MA: $14.75
$17.46
52-Week Range
$6.02
Now: $12.69
$18.42
Volume112,795 shs
Average Volume107,625 shs
Market Capitalization$322.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3
Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica Pharmaceuticals Inc. was founded in 2013 and is headquartered in West Chester, Pennsylvania.
Verrica Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRCA
CUSIPN/A
CIKN/A
Phone484-453-3300
Employees17
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.52 per share

Profitability

Net Income$-28,210,000.00

Miscellaneous

Market Cap$322.85 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update
March 31, 2021 |  americanbankingnews.com
VERRICA PHARMAC. DL-,0001 (1NE.BE)
March 21, 2021 |  in.finance.yahoo.com
Vectoring Back In On Verrica Pharmaceuticals
February 19, 2021 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

349th out of 2,025 stocks

Pharmaceutical Preparations Industry

161st out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
$12.69
-1.00 (-7.30 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRCA News and Ratings via Email

Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

Is Verrica Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Verrica Pharmaceuticals stock.
View analyst ratings for Verrica Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Verrica Pharmaceuticals?

Wall Street analysts have given Verrica Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Verrica Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 1,120,000 shares, a decrease of 24.3% from the February 28th total of 1,480,000 shares. Based on an average trading volume of 99,700 shares, the days-to-cover ratio is currently 11.2 days. Currently, 7.7% of the shares of the company are sold short.
View Verrica Pharmaceuticals' Short Interest
.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Verrica Pharmaceuticals
.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) issued its earnings results on Wednesday, March, 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.10.
View Verrica Pharmaceuticals' earnings history
.

How has Verrica Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VRCA stock has increased by 20.6% and is now trading at $12.69.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for VRCA?

4 Wall Street analysts have issued 12-month target prices for Verrica Pharmaceuticals' stock. Their forecasts range from $10.00 to $24.00. On average, they anticipate Verrica Pharmaceuticals' stock price to reach $17.75 in the next year. This suggests a possible upside of 39.9% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:
  • Mr. Ted White, Pres, CEO & Director (Age 56, Pay $666.19k)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 54, Pay $342.85k)
  • Mr. Joe Bonaccorso, Chief Commercial Officer (Age 57, Pay $528.11k)
  • Dr. Gary Goldenberg M.D., Chief Medical Officer (Age 44, Pay $55k)
  • Mr. Christopher G. Hayes, Chief Legal Officer, Sec. & Gen. Counsel (Age 57)
  • Mr. Eugene Scavola, Exec. VP of Technical Operations
  • Dr. Bradley J. Catalone MBA, Ph.D., Head of Drug Devel.

Who are some of Verrica Pharmaceuticals' key competitors?

What other stocks do shareholders of Verrica Pharmaceuticals own?

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $12.69.

How much money does Verrica Pharmaceuticals make?

Verrica Pharmaceuticals has a market capitalization of $322.85 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How many employees does Verrica Pharmaceuticals have?

Verrica Pharmaceuticals employs 17 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

Where are Verrica Pharmaceuticals' headquarters?

Verrica Pharmaceuticals is headquartered at 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.